Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals.
Steudel
Wolfgang
W
Clinical Research & Development, Department of Anesthesiology, University of Colorado Denver, Bioscience East, Suite 100, 1999 North Fitzsimons Parkway, Aurora, CO 80045-7503, USA.
Dingmann
Colleen
C
Zhang
Yan-Ling
YL
Bendrick-Peart
Jamie
J
Clavijo
Claudia
C
Shulze
John
J
Betts
Ronald
R
Christians
Uwe
U
D000328:Adult; D049109:Cell Proliferation / Q000187:drug effects; D002853:Chromatography, Liquid; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006207:Half-Life; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D053719:Tandem Mass Spectrometry; D014018:Tissue Distribution; D055815:Young Adult
D007166:Immunosuppressive Agents; C518022:umirolimus; D020123:Sirolimus